Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Charles Moore-Kelly
Institution:
Oxford BioMedica (United Kingdom)
Observed institution:
Oxford BioMedica (United Kingdom)
ORCID:
0009-0005-2560-5756
Observed ORCID:
0009-0005-2560-5756
OpenAlex ID:
A5117479581
Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward reduced testing?
2025
·
Daniel Farley
, Samuel Stockdale
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
5
PDF
Enhancing titers of therapeutic lentiviral vectors using PKC agonists
2025
·
Charles Moore-Kelly
, Rajesh Reddem
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
5
PDF
Rethinking viral vector quantification: a microfluidic approach to standardised functional titre assays
2026
·
Daria Andreea Farcas
, Charles Moore-Kelly
, et al.
·
Frontiers in Bioengineering and Biotechnology
·
2
PDF
Show more works
View as search
Works count:
3
Citation count:
12
H-index:
2
I10-index:
Year
Topic
Type